MariTides potential benefits include: Monthly dosing Significant weight loss Strong improvements in cardiometabolic markers A novel GIPR-blocking mechanism Extended half-life via antibody technology Early results showing improvements in blood sugar, HbA1c, and potentially blood pressure If approved, MariTide could offer a new option for millions living with obesity, type 2 diabetes, or related conditions like sleep apnea and cardiovascular disease
10.1097/NEN.0b013e31818b4906 297 SasakiY.ArakiT.MilbrandtJ
The receptive field surround of GCs may be generated by feedforward inhibition directly onto GCs [75] or presynaptically, by GABAergic feedback inhibition from amacrine cells onto bipolar cell axons [77, 78]
Orforglipron has the potential to redefine the maintenance phase of obesity care, says Fatima Cody Stanford, MD, MPH, an obesity medicine physician-scientist and an associate professor of medicine and pediatrics at Harvard Medical School in Boston, who was not involved in the trial
Why Am I Not Losing Weight on GLP-1s
Additionally, women, who are more likely to have a fear of needles than men, represented 80% of the patients in this data set